<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00705263</url>
  </required_header>
  <id_info>
    <org_study_id>P04244</org_study_id>
    <nct_id>NCT00705263</nct_id>
  </id_info>
  <brief_title>Satisfaction in Patients Receiving the PegIntron Pen Plus Rebetol for Hepatitis C (Study P04244)(COMPLETED)</brief_title>
  <official_title>Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C in Slovenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Schering-Plough</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Schering-Plough</source>
  <oversight_info>
    <authority>Slovenia: Agency for Medicinal Products - Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current gold standard for treatment of chronic hepatitis C is pegylated interferon plus
      ribavirin. Drug administration accuracy and ease of use will definitely determine treatment
      effectiveness. This is the idea behind the development and usage of the PegIntron pen
      (PegPen). Therefore, it is worthwhile to evaluate patients' satisfaction with this novel
      device. The results of the study will be used to improve PegPen training techniques for
      patients and health care providers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Number of Participants Satisfied With the PegIntron Pen, Including the Assessment of the Device Accuracy and Ease of Use.</measure>
    <time_frame>After 4 weeks of treatment.</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">113</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <condition>Hepacivirus</condition>
  <arm_group>
    <arm_group_label>Patients with chronic hepatitis C</arm_group_label>
    <description>Patients with chronic hepatitis C who are treated with the PegIntron pen plus Rebetol will answer questions on the patient questionnaire.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Peginterferon alfa-2b (SCH 54031)</intervention_name>
    <description>Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.</description>
    <arm_group_label>Patients with chronic hepatitis C</arm_group_label>
    <other_name>PegIntron, PegPen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin (SCH 18908)</intervention_name>
    <description>Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.</description>
    <arm_group_label>Patients with chronic hepatitis C</arm_group_label>
    <other_name>Rebetol</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chronic hepatitis C treated with the PegIntron pen plus Rebetol at sites in
        Slovenia.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with chronic hepatitis C treated with the PegIntron pen plus Rebetol

        Exclusion Criteria:

          -  Not willing to participate in the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2009</verification_date>
  <lastchanged_date>August 20, 2009</lastchanged_date>
  <firstreceived_date>June 23, 2008</firstreceived_date>
  <firstreceived_results_date>May 28, 2009</firstreceived_results_date>
  <responsible_party>
    <name_title>Head, Clinical Trials Registry &amp; Results Disclosure Group</name_title>
    <organization>Schering-Plough</organization>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
